Logo image of TNXP

TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Fundamental Analysis

USA - NASDAQ:TNXP - US8902608392 - Common Stock

18.81 USD
-0.69 (-3.54%)
Last: 10/16/2025, 4:02:06 PM
18.81 USD
0 (0%)
After Hours: 10/16/2025, 4:02:06 PM
Fundamental Rating

3

Overall TNXP gets a fundamental rating of 3 out of 10. We evaluated TNXP against 536 industry peers in the Biotechnology industry. TNXP has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, TNXP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TNXP has reported negative net income.
TNXP had a negative operating cash flow in the past year.
TNXP had negative earnings in each of the past 5 years.
In the past 5 years TNXP always reported negative operating cash flow.
TNXP Yearly Net Income VS EBIT VS OCF VS FCFTNXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -43.46%, TNXP is in line with its industry, outperforming 55.78% of the companies in the same industry.
TNXP's Return On Equity of -48.47% is fine compared to the rest of the industry. TNXP outperforms 66.98% of its industry peers.
Industry RankSector Rank
ROA -43.46%
ROE -48.47%
ROIC N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
TNXP Yearly ROA, ROE, ROICTNXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

TNXP's Gross Margin of 29.27% is fine compared to the rest of the industry. TNXP outperforms 73.51% of its industry peers.
The Profit Margin and Operating Margin are not available for TNXP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNXP Yearly Profit, Operating, Gross MarginsTNXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TNXP has been increased compared to 1 year ago.
Compared to 5 years ago, TNXP has more shares outstanding
Compared to 1 year ago, TNXP has an improved debt to assets ratio.
TNXP Yearly Shares OutstandingTNXP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
TNXP Yearly Total Debt VS Total AssetsTNXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -1.10, we must say that TNXP is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TNXP (-1.10) is comparable to the rest of the industry.
There is no outstanding debt for TNXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.1
ROIC/WACCN/A
WACC9.67%
TNXP Yearly LT Debt VS Equity VS FCFTNXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 7.53 indicates that TNXP has no problem at all paying its short term obligations.
With a decent Current ratio value of 7.53, TNXP is doing good in the industry, outperforming 71.27% of the companies in the same industry.
A Quick Ratio of 7.22 indicates that TNXP has no problem at all paying its short term obligations.
TNXP's Quick ratio of 7.22 is fine compared to the rest of the industry. TNXP outperforms 70.71% of its industry peers.
Industry RankSector Rank
Current Ratio 7.53
Quick Ratio 7.22
TNXP Yearly Current Assets VS Current LiabilitesTNXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.64% over the past year.
Looking at the last year, TNXP shows a very negative growth in Revenue. The Revenue has decreased by -21.09% in the last year.
EPS 1Y (TTM)99.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.8%
Revenue 1Y (TTM)-21.09%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-9.51%

3.2 Future

The Earnings Per Share is expected to grow by 25.99% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 118.28% on average over the next years. This is a very strong growth
EPS Next Y99.48%
EPS Next 2Y41.3%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year-10.16%
Revenue Next 2Y204.72%
Revenue Next 3Y118.28%
Revenue Next 5YN/A

3.3 Evolution

TNXP Yearly Revenue VS EstimatesTNXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
TNXP Yearly EPS VS EstimatesTNXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -500M -1B -1.5B

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TNXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TNXP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNXP Price Earnings VS Forward Price EarningsTNXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNXP Per share dataTNXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as TNXP's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.3%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

TNXP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (10/16/2025, 4:02:06 PM)

After market: 18.81 0 (0%)

18.81

-0.69 (-3.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners15.84%
Inst Owner Change0%
Ins Owners0.06%
Ins Owner Change3.33%
Market Cap164.96M
Analysts82.5
Price Target69.02 (266.93%)
Short Float %15.21%
Short Ratio0.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.95%
Min EPS beat(2)-17.71%
Max EPS beat(2)13.8%
EPS beat(4)3
Avg EPS beat(4)46.48%
Min EPS beat(4)-17.71%
Max EPS beat(4)97.53%
EPS beat(8)5
Avg EPS beat(8)-26.06%
EPS beat(12)8
Avg EPS beat(12)-11.59%
EPS beat(16)10
Avg EPS beat(16)-6.96%
Revenue beat(2)0
Avg Revenue beat(2)-13.06%
Min Revenue beat(2)-19.5%
Max Revenue beat(2)-6.61%
Revenue beat(4)0
Avg Revenue beat(4)-16.01%
Min Revenue beat(4)-27.68%
Max Revenue beat(4)-6.61%
Revenue beat(8)0
Avg Revenue beat(8)-21.76%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.73%
PT rev (3m)-83.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.91%
EPS NY rev (1m)0%
EPS NY rev (3m)1.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.78
P/FCF N/A
P/OCF N/A
P/B 0.98
P/tB 0.98
EV/EBITDA N/A
EPS(TTM)-39.47
EYN/A
EPS(NY)-8.78
Fwd EYN/A
FCF(TTM)-7.46
FCFYN/A
OCF(TTM)-7.39
OCFYN/A
SpS1.12
BVpS19.16
TBVpS19.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.46%
ROE -48.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.27%
FCFM N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.5%
Cap/Sales 5.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.53
Quick Ratio 7.22
Altman-Z -1.1
F-Score5
WACC9.67%
ROIC/WACCN/A
Cap/Depr(3y)1346.5%
Cap/Depr(5y)20638.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.8%
EPS Next Y99.48%
EPS Next 2Y41.3%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)-21.09%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-9.51%
Revenue Next Year-10.16%
Revenue Next 2Y204.72%
Revenue Next 3Y118.28%
Revenue Next 5YN/A
EBIT growth 1Y13.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.5%
OCF growth 3YN/A
OCF growth 5YN/A